Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

In a recent interview Edico Genome's CEO describes how the company's technology can process genomics big data both rapidly and accurately.

Device financing decreased to $734 million in Q3, less than half the Q2 total, and the $4.9 billion in M&As was a sharp decline versus Q2. Diagnostics fundraising, at $399 million, showed a 31% drop from Q2, and Merck KGAA’s $16.7 billion buy of Sigma-Aldrich made up 96% of the Q3 M&A activity.